US News

FDA seeks probe into its talks with Biogen before Alzheimer’s drug approval

Published by

By Manas Mishra (Reuters) -The U.S. drug regulator on Friday called for an independent federal probe into the interactions between its representatives and Biogen Inc that led to the approval of the company Alzheimer’s disease drug last month. The drugmaker’s shares fell 3% after the agency’s acting commissioner Janet Woodcock asked the Office of the Inspector General at the Department of Health and Human Services to probe if the talks were inconsistent with the regulator’s policies. Biogen said it will cooperate with any inquiry in connection to a possible review. The drug, Aduhelm, was approv…

Read More

Facebook Comments

Check Also

Haiti police say former Supreme Court judge suspect in president’s killing

Published by Reuters PORT-AU-PRINCE (Reuters) – Haitian police ...